What factors drove the changes in Innate Pharma's revenue and profit?

What guidance did Innate Pharma's management provide for the next earnings period?

What were the key takeaways from Innate Pharma's earnings call?

What does Innate Pharma do and what are its main business segments?

What is Innate Pharma's gross profit margin?

Did Innate Pharma beat or miss consensus estimates last quarter?

What is the market's earnings forecast for Innate Pharma next quarter?

What is the revenue and EPS growth rate for Innate Pharma year over year?

- **Strategic Focus**: Three assets (IPH4502, lacutamab, monalizumab) drive growth, with phase III trials for lacutamab (H2 2026) and monalizumab (data H2 2026).
- **Financial Strength**: EUR 44.8M cash, funding until Q3 2026; AstraZeneca partnerships worth up to $2.16B in milestones.
- **Clinical Progress**: IPH4502 shows activity in post-PADCEV bladder cancer; lacutamab trial design finalized for CTCL.
- **Partnership Updates**: MATISSE trial interim data at AACR; lacutamab financing discussions prioritize shareholder value.

**【CEO Summary Section】**
- Focused on three high-value assets: IPH4502 (Nectin-4 ADC), lacutamab (CTCL), and monalizumab (anti-NKG2A). Streamlined operations with a redundancy plan to enhance efficiency.
- Phase III TELLOMAK 3 trial for lacutamab in CTCL expected to initiate H2 2026, with potential accelerated approval in Sézary syndrome.
- Monalizumab's PACIFIC-9 trial in NSCLC nearing data readout (H2 2026), with AstraZeneca handling development costs and milestones worth up to $1.275 billion.

**【CMO Updates】**
- **IPH4502**: Phase I trial shows preliminary antitumor activity in post-PADCEV urothelial cancer with favorable safety. Differentiated by exatecan payload and hydrophilic linker, targeting low Nectin-4 tumors.
- **Lacutamab**: Phase III trial design compares lacutamab vs romidepsin/mogamulizumab in CTCL, with PFS as primary endpoint. FDA clearance received, enrollment expected to begin H2 2026.
- **Monalizumab**: PACIFIC-9 trial completed enrollment (999 pts), evaluating durvalumab + monalizumab vs durvalumab alone in NSCLC.

**【COO Financial Terms】**
- **Monalizumab**: Up to $1.275 billion in milestones, including $450M received. Royalties on U.S./ROW sales; 50% profit share in Europe with co-promotion option.
- **IPH5201**: Up to $885M in milestones, similar structure to monalizumab with potential co-promotion in Europe.

**【CFO Financial Results】**
- 2025 revenue: EUR 9M (licensing + gov funding). R&D expenses down 16% YoY to EUR 43.6M. Cash position: EUR 44.8M (funding visibility until Q3 2026).

**【Q&A Highlights】**
- **IPH4502 Competition**: Differentiated by exatecan payload and ability to target low Nectin-4 tumors; no direct competitors in post-PADCEV setting.
- **MATISSE Trial**: Interim data to be presented at AACR, focusing on CD39/CD73 axis in early-stage lung cancer. AZ retains option to co-develop.
- **Lacutamab Partnerships**: Exploring non-dilutive financing (royalty-backed or BD) to fund phase III, with preference for structures preserving long-term value.

Innate Pharma SA (IPHA) Q4 2025 Earnings Call Transcript

- **Pipeline Momentum**: Lacutamab on track for FDA approval in Sézary syndrome by H2 2027; IPH4502 Phase I data expected H1 2026.
- **Financial Strength**: EUR 56.4M cash runway through Q3 2026; focused on derisked development strategy.
- **Strategic Priorities**: Monalizumab Phase III readout (H2 2026), IPH4502 expansion into post-PADCEV bladder cancer, and ANKET platform deprioritization.

**【CEO Summary Section】**
- CEO Jonathan Dickinson highlighted strong progress across the pipeline, emphasizing lacutamab's potential for accelerated approval in Sézary syndrome by mid-2027. The company is prioritizing three key assets: IPH4502 (Nectin-4 ADC), monalizumab (anti-KIR3DL2), and lacutamab (anti-KIR3DL2). The Phase I trial for IPH4502 in urothelial cancer (post-PADCEV) is on track to complete dose escalation by Q1 2026, with early signs of clinical activity.

**【CMO Financial Commentary】**
- CFO noted a cash position of EUR 56.4 million as of Q3 2025, providing runway through Q3 2026. Key upcoming milestones include Phase I data for IPH4502 (H1 2026), Phase III monalizumab results (H2 2026), and FDA approval for lacutamab in Sézary syndrome (H2 2027). The company is focused on derisking development through adaptive trial designs and partnerships (e.g., AstraZeneca for monalizumab).

**【Q&A Highlights】**
- **Commercial Readiness**: Lacutamab's BLA submission is contingent on initiating the confirmatory Phase III trial by H1 2026, with FDA approval expected in H2 2027. The company is engaging KOLs to include lacutamab in NCCN guidelines pre-launch.
- **Partnership Strategy**: While open to partnerships, the company is prioritizing internal execution for high-value assets (e.g., IPH4502, lacutamab). ANKET platform assets (IPH6501, IPH6101) are being deprioritized based on clinical data.
- **Safety Signals**: IPH4502 shows no MMAE-related toxicities (e.g., neuropathy), positioning it as a safer alternative to PADCEV in urothelial cancer. Early data suggest activity in Nectin-4-low tumors, expanding potential addressable market.

Innate Pharma S.A. (IPHA) Q3 2025 Earnings Call Transcript

- **Strategic Refocus**: Prioritizing IPH4502, lacutamab, and monalizumab to maximize value.
- **Pipeline Momentum**: IPH4502 Phase I on track for H1 2026 data; lacutamab nearing Phase III submission.
- **Financial Stability**: €70.4M cash runway until Q3 2026; collaboration revenue supports operations.
- **Partnership Strength**: AstraZeneca's Phase III trial for monalizumab progressing with €1.275B potential deal value.

**【CEO Strategic Remarks】**
- Focused on three high-value assets: IPH4502 (ADC), lacutamab (anti-KIR3DL2), and monalizumab (anti-NKG2A).
- Streamlined organization to prioritize near-term milestones and improve operational efficiency.
- CSO Eric Vivier transitioning to academic research but maintaining advisory role, with Yannis Morel assuming CSO responsibilities.

**【COO ADC Discussion (IPH4502)】**
- Differentiated Nectin-4 ADC with exatecan payload, designed to overcome PADCEV limitations.
- Preclinical data shows efficacy in PADCEV-resistant models and low Nectin-4 expression tumors.
- Targeting urothelial cancer post-PADCEV and broadening to other solid tumors.

**【CMO Clinical Updates】**
- **IPH4502**: Phase I enrollment on track for Q1 2026 completion; expects 50-60 patient data readout in H1 2026.
- **Lacutamab**: FDA Breakthrough Therapy Designation for Sézary syndrome; Phase III protocol nearing submission with potential accelerated approval in 2027.
- **Monalizumab**: AstraZeneca's Phase III PACIFIC-9 trial fully recruited, with data expected H2 2026.

**【CFO Financial Overview】**
- H1 2025 revenue: €4.9M (collaborations with AstraZeneca/Sanofi, government grants).
- Operating expenses: €30.3M (R&D: €20.5M, G&A: €9.8M).
- Cash runway: €70.4M as of June 2025, sufficient until Q3 2026.

**【Q&A Highlights】**
- **NK Cell Assets**: Lower priority; future decisions based on clinical data relevance.
- **Sanofi's ANKET**: Progressing BCMA-targeted program in autoimmunity.
- **Lacutamab Funding**: Exploring investor and partner options for Phase III; interest driven by expanded market opportunity.
- **IPH4502 Enrollment**: 50-60 patients expected by H1 2026; safety and efficacy data to guide next steps.

Innate Pharma S.A. (IPHA) Q2 2025 Earnings Call Transcript

- **Strategic Growth**: Emphasizes NK-Cell Engagers (ANKET) and ADCs, with eight clinical assets.
- **Key Assets**: IPH6501 (CD20 ANKET) and IPH4502 (Nectin-4 ADC) advancing rapidly; lacutamab with FDA BTD for Sezary syndrome.
- **Partnerships**: €50M Sanofi investment and return of IPH6101 rights; Phase 3 discussions for lacutamab.
- **Financial Position**: €72.5M cash, supporting operations through mid-2026.

**【CEO Summary Section】**
- **Strategic Focus**: Three pillars - NK-Cell Engagers (ANKET), ADCs, and late-stage assets. Key programs include IPH65 (CD20 ANKET), IPH6101 (CD123 ANKET), and IPH45 (Nectin-4 ADC).
- **Pipeline Updates**: Eight assets in clinical development, with four proprietary (IPH6501, IPH4502, lacutamab, monalizumab) and four partnered. Upcoming ASCO presentations on lacutamab and IPH4502.
- **Sanofi Partnership**: €50M equity investment (9% stake) and return of IPH6101 rights. Sanofi pivoting IPH6401 (BCMA ANKET) to autoimmune diseases.
- **Financial Position**: €72.5M cash as of Q1, excluding €15M from Sanofi, supporting operations through mid-2026.

**【COO and CMO Updates】**
- **ANKET Platform**: IPH6501 (CD20 ANKET) in Phase 1 for B-cell lymphomas, with potential for autoimmune diseases. Preclinical data shows superior efficacy and reduced cytokine release vs. T-cell engagers.
- **ADC Platform**: IPH4502 (Nectin-4 ADC) in Phase 1, targeting heterogeneous Nectin-4 expression. Preclinical data shows resistance to MMAE and activity in low-expression models.
- **Clinical Assets**: Lacutamab (anti-KIR3DL2) with FDA BTD for Sezary syndrome, Phase 3 discussions underway. Monalizumab (AZ-partnered) in Phase 3 for NSCLC.

**【Q&A Highlights】**
- **IPH6101 Strategy**: Data review from Sanofi expected by July; decision on refractory vs. first-line AML setting pending. Potential partnership or internal funding.
- **Financial Strategy**: Focus on advancing IPH6501 and IPH4502 to key decision points. Seeking partnerships for lacutamab Phase 3, with preference for non-dilutive funding.
- **B7H3 ANKET**: Sanofi's IPH6201 (B7H3 ANKET) in preclinical; NK-cell engager mechanism offers differentiation from ADCs in crowded landscape.

Innate Pharma S.A. (IPHA) Q1 2025 Earnings Call Transcript

- **Lacutamab Regulatory Momentum**: ASCO 2024 MF data pivotal for FDA; potential accelerated approval in Sezary.
- **ADC Innovation**: IPH45 designed to overcome MMAE resistance, with IND filing planned.
- **ANKET Expansion**: IPH6501 Phase 1/2 trial underway; ANKET platform versatility.
- **Financial Stability**: €115M cash runway; no milestones assumed in 2024-2025 forecast.

**【CEO Summary Section】**
- Focused on three pillars: near-term value from lacutamab, pipeline growth via ANKET/ADC, and strategic partnerships (e.g., AstraZeneca).
- Lacutamab ASCO 2024 MF data to define regulatory path; IPH45 ADC IND filing planned.
- €115M cash runway to end-2025, excluding milestones.

**【CMO & COO Updates】**
- Lacutamab: ASCO 2024 MF data pivotal for FDA; IPH45 ADC targeting MMAE-resistant cancers.
- ANKET/IPH6501 Phase 1/2 trial underway; Sanofi ANKET Phase 2.

**【Q&A Highlights】**
- Regulatory focus on accelerated approval in Sezary; ASCO data critical.
- IPH45 designed to overcome MMAE resistance; IND filing planned.
- ANKET versatility in oncology and autoimmune diseases.
- €115M cash; no milestones assumed in cash forecast.

Actual																				-0.3492
Forecast																				-0.3492
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Actual	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	5.70M
Forecast	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	5.70M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

IPHA

IPHA fundamentals

IPHA Q4 2025 Earnings

Earnings Call

You can ask Aime

IPHA

IPHA fundamentals

IPHA Q4 2025 Earnings

Earnings Call

IPHA Earnings Call Summary for Q4/20254:00 AM on Mar 26, 2026

IPHA Earnings Call Summary for Q3/20258:00 AM on Nov 13, 2025

IPHA Earnings Call Summary for Q2/20258:00 AM on Sep 17, 2025

IPHA Earnings Call Summary for Q1/20258:00 AM on May 13, 2025

IPHA Earnings Call Summary for Q4/2024 Mar 28, 2026

You can ask Aime